Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma

Abstract TNB‐383B is a fully human BCMA‐targeting T‐cell engaging bispecific monoclonal antibody (T‐BsAb). We assessed ex vivo efficacy of this drug to mediate killing of bone marrow mononuclear cells (BMMCs) freshly isolated from 10 patients with relapsed multiple myeloma (MM). BMMC were treated ex...

Full description

Bibliographic Details
Main Authors: David M. Foureau, Manisha Bhutani, Myra Robinson, Fei Guo, Duy Pham, Ben Buelow, Nury Steuerwald, Katherine Rigby, Elise Tjaden, Marina Leonidas, Barry A. Paul, Shebli Atrash, Ami Ndiaye, James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:eJHaem
Subjects:
antibody therapy
immunophenotyping
myeloma
Online Access:https://doi.org/10.1002/jha2.69

Internet

https://doi.org/10.1002/jha2.69

Similar Items